When Mylan and Perrigo executives had a “very preliminary” discussion a year ago about possibly merging the two generic drug companies, Perrigo was a different company, according to its CEO Joe Papa.
Back then, the over-the-counter medications specialist was doing business in six countries and looking for a way to dramatically expand its reach. Today, after taking over Belgian-based Omega Pharma Invest in March, Perrigo has expanded to 39 countries.
With the expansion problem resolved, Ireland-based Perrigo is now better equipped to deliver strong growth as an independent company, Mr. Papa told investors at a Deutsche Bank health care conference in Boston on Wednesday.
“We believe we have a business that will grow 5 percent to 10 percent organically,” Mr. Papa said during a presentation devoted almost entirely to answering questions about the company’s rationale for spurning three unsolicited takeover offers in recent weeks from Mylan.
Mr. Papa reiterated the board’s contention that the offers were too low — by a wide margin. Still, since Perrigo is a public company with a fiduciary duty to shareholders, an eventual sale can’t be ruled out, he said.
“There is a number at some point” that the board would accept, he said. But so far, “We aren’t anywhere close to that.”
Read More
Mr. Papa said Mylan’s takeover proposal was complicated by the introduction of Teva Pharmaceutical Industries’ $82-a-share offer to buy Mylan, which Mylan has so far rejected.
“There is uncertainty about what’s going to happen with Teva/Mylan,” he said. “That’s part of the uncertainty about Perrigo/Mylan.”
Mylan, which is run from its operations base in Cecil, has said it would continue to pursue Perrigo by taking its latest proposal directly to shareholders.
Mr. Papa said he believed that concessions Mylan sought under takeover rules in Ireland — where Perrigo reincorporated through an inversion in 2013 — would give Mylan until mid-September to launch an official solicitation of Perrigo shares.
“This process may take some time to get resolved,” Mr. Papa said.
Teva also has vowed to push ahead with its bid for Mylan. The Israel-based company reportedly has been meeting with Mylan’s biggest investors to try to win their support.
One large shareholder — billionaire John Paulson’s hedge fund Paulson & Co. — recently boosted its stake in Mylan to 22 million shares, or 4.5 percent of the company, up from 15 million, or 3 percent. The move ignited talk that Mr. Paulson was seeking to exert more pressure on Mylan’s board to accept an offer from Teva.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.